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Summary:
We report a 39-year-old female patient who underwent
HLA-identical sibling allogeneic BMT for CML in
accelerated phase. Severe pancytopenia refractory to G-
CSF associated with progressive splenomegaly and RBC/
platelet transfusion dependency were present from day
+60 after BMT. MRD assessed by FISH and RT-PCR
multiplex for BCR-ABL rearrangement was negative, and
complete chimerism was documented by VNTR on days
+100, +180, +360 and 2 years after BMT. Splenect-
omy was performed on day +225 and pancytopenia
resolved but chronic extensive graft-versus-host disease
developed, with hepatic cholestasis, diffuse scleroderma
and sicca-like syndrome. She was sequentially and
progressively treated with different immunosuppressive
therapy combinations with no clear beneﬁt. On day +940,
she presented with infection over the previously present
ulcers on both limbs, which culminated in septic shock
and death on day +1041. We conclude that, although
splenectomy may reverse poor graft function after
allogeneic BMT, hyposplenism may trigger or worsen
chronic extensive GVHD leading to increased morbidity
and mortality.
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Allogeneic BMT is a therapeutic option for many
hematologic malignancies and the only curative available
treatment for CML to date. Graft-versus-host disease
(GVHD) remains one of the major complications and has
a high mortality rate. Splenectomy has been undertaken to
reverse poor graft function because of hypersplenism after
allogeneic BMT, with satisfactory results.1–3 Previous
studies indicate that surgical or functional postallogeneic
BMT hyposplenism may be associated with a higher
incidence of chronic extensive GVHD.4 However there
are conﬂicting data in the literature about the relationship
between splenectomy and worsening of GVHD.5–8 We
report a case in which this association clearly occurred.
Case report
39-year-old female patient presented with fatigue and
abdominal fullness. Massive splenomegaly was found and
WBC showed marked leukocytosis (160 109/l) with left-
shifted myeloid series and basophilia. Bone marrow
aspiration and Ph1 chromosome positivity conﬁrmed the
diagnosis of CML. She was admitted for HLA identical
sibling donor BMT, and the conditioning regimen consisted
of busulphan (16mg/kg)/cyclophosphamide (120mg/kg).9
GVHD prophylaxis consisted of short-term methotrexate
plus cyclosporine (CyS).10 Engraftment occurred on day
+28. On day +60, a routine CBC showed pancytopenia
(WBC 2.2 109/l with ANC 0.602 109/l, hemoglobin
of 7.2 g/dl and platelet count of 23 109/l) associated with
progressive splenomegaly. Bone marrow aspiration and
biopsy revealed a normocellular marrow. Over the next
5 months, she had eight febrile neutropenic episodes
requiring hospital admission and treatment with broad-
spectrum antibiotics. Daily subcutaneous 5mg/kg G-CSF
infusions were given for 14 days with no improvement. She
received a total of 19U of RBC and 75 random units
of platelets. G-Band karyotyping was normal. MRD
searched by FISH and RT-PCR multiplex for BCR-ABL
rearrangements were negative and complete chimerism was
documented by VNTR on days +100, +180, +360 and 2
years after BMT. We concluded that the patient was
entirely donor on chimerism studies and had evidence of
hypersplenism.
As she remained pancytopenic and transfusion depen-
dent for more than 7 months after BMT, splenectomy was
performed on day +225. The spleen had no morphological
or cytogenetic evidence of tumor. Pancytopenia and
dependency on transfusion resolved after splenectomy.
Edema and rash in both forearms and hands were seen
on day +260 and evolved into a diffuse scleroderma
(Figure 1). As part of the extensive c-GVHD, a sicca-like
syndrome and liver cholestasis were diagnosed at that time.
She was sequentially treated with CyS plus prednisone and
weekly high-dose immunoglobulin infusions. CyS was
discontinued on day +921 because of acute renal failure.
On day +486, she developed Herpes Zoster lesions on the
trunk that progressed to local ulceration with secondaryReceived 1 November 2002; accepted 3 February 2003
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infection and concomitant ulceration of both limbs
(Figure 2). She underwent hyperbaric oxygen therapy with
some recovery. The generalized scleroderma evolved to
affect the trunk and limbs. A year post transplant, PUVA
therapy associated with daily MMF (2 g), thalidomide
(600mg) and prednisone (80mg) were sequentially and
progressively initiated. Several admissions for infectious
complications were required. On day +1034, she had a
Staphylococcus aureus systemic infection with worsening of
the limb ulceration, culminating in septic shock and death
on day +1041.
Discussion
We describe a patient who underwent allogeneic BMT for
CML in accelerated phase and developed a severe and
persistent pancytopenia in the post transplant period
associated with splenomegaly and hypersplenism. Splenect-
omy was performed and the pancytopenia resolved, but a
progressive de novo chronic extensive GVHD emerged after
the surgery. All immunosuppressive measures adopted
failed to change the course of the chronic GVHD which
had a fatal outcome.
Post transplant hypersplenism was ﬁrst described in 1992
and should be considered in patients presenting with
pancytopenia and splenomegaly after allogeneic BMT. It
has been associated with splenic hypervascularity, and
expanded vascular capacity and proliferation of infused
stem cells in the spleen, possibly related to physical
impediment of ﬂow.3 Splenectomy has been shown to
resolve pancytopenia in 11 previously reported cases, with
no associated comorbidity.1–3 Accordingly, in the present
case, splenectomy successfully resolved the pancytopenia.
There is controversy in the literature regarding the
relationship between splenectomy and chronic GVHD.
Ringde´n et al5 have shown an increased incidence of acute
GVHD and higher death rate in patients splenectomized
before BMT. The same European group conﬁrmed later
that splenectomy was an important risk factor for acute
and chronic GVHD on bivariate analysis and in only
chronic GVHD on multivariate analysis.6 Michallet et al7
evaluated 157 patients who underwent BMT from an HLA-
identical sibling and found that splenectomy was the most
important factor determining GVHD severity on multi-
variate analysis. However, a more recent retrospective
analysis to evaluate the role of splenectomy on BMT
outcome showed no signiﬁcant inﬂuence of splenectomy on
acute or chronic GVHD, although it was associated with an
increased risk for all grades of acute GVHD, but this was
not statistically signiﬁcant.8
The exact mechanism of the inﬂuence of splenectomy on
GVHD incidence and severity is not known. The most
likely hypothesis is that the spleen functions as a ‘ﬁlter’ for
activated T cells by the activity of HLA-DR and CD1a-
positive cells (dendritic cells).11 Donor-derived alloreactive
T cells, post-thymic activated CD4+ T cells and T cells
immunoreactive to minor HLA antigens, which are
extremely important in the pathogenesis of chronic GVHD,
could then possibly be ‘cleared’ by the spleen. By this
mechanism, the spleen may also play a role in modulating
the activation of different helper T-cell subsets (Th1 vs Th2)
minimizing the effects of cytokines secreted by Th2 cells
(IL-4, IL-5, IL-10), which predominate in chronic
GVHD.12 The other two hypotheses include the role of
the spleen in the modulation of infections,13 and its
production of an immunosuppressive peptide in animal
studies, never found in human studies.14 Infection was
Figure 1 Sclero-like lesions.
Figure 2 Limb ulcerations.
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constantly present in this case: before splenectomy because
of severe neutropenia and after splenectomy because of
severe chronic GVHD, despite a normal neutrophil count.
We believe that infection was also an important risk factor
in the development of chronic GVHD in this case.
It is also important to emphasize that the patient
remained in continuous complete remission during the
whole post transplant period and that a chronic GVHD-
associated GVL effect may have had an important role.
We conclude that, although splenectomy may reverse
poor graft function after allogeneic BMT, surgical hypo-
splenia may trigger or worsen chronic extensive GVHD
leading to an increase in morbidity and mortality.
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